Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,200 across all filing types
Latest filing 2023-10-04 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the USFDA approval of a pharmaceutical product by Strides Pharma Science Limited. It is dated October 4, 2023, and contains no financial statements, regulatory certifications, or detailed financial data. The content focuses on product approval news and company background, typical of a press release. The document length is 4338 characters, which is relatively short and consistent with a press release rather than a detailed financial or regulatory filing. There is no indication that this is an Annual Report, Earnings Release, or any other detailed financial or regulatory document. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements and press releases that do not fit other categories.
2023-10-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is titled 'Investor Call transcript' and references an investor call held on September 25, 2023. It contains a detailed transcript of the conference call including management introductions, discussions of financial performance, business strategy, and outlook. The text includes direct speech from company executives and covers forward-looking statements, financial guidance, and operational updates. There is no indication that this is a brief announcement or a report publication notice; rather, it is the full transcript of the investor call. Therefore, the document fits the definition of a Call Transcript (CT).
2023-10-03 English
Press Release (Revised)
Capital/Financing Update Classification · 95% confidence The document is an updated press release from Strides Pharma Science Limited announcing USFDA approval for a pharmaceutical product. It is a public communication about a regulatory milestone and product launch, not a financial report, earnings release, or regulatory filing. The document is relatively short (4556 characters) and is clearly labeled as a press release update. It does not contain financial statements, management discussion, or detailed investor information. Therefore, it fits best under the category of Capital/Financing Update (CAP) as it relates to a significant business development impacting the company's product portfolio and market opportunity.
2023-10-03 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a short letter addressed to stock exchanges regarding the audio recording of an investor call held on September 25, 2023. It references the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and provides a link to the audio recording of the investors call. The document does not contain any financial data, analysis, or detailed transcript but is an announcement about the availability of the call recording. The length is only 1162 characters, which is very short and fits the pattern of an announcement rather than the full transcript or report. Therefore, this document is best classified as a Call Transcript announcement or related to the call, but since it only provides a link to the audio recording and not the transcript itself, it is an announcement about the call recording. Given the filing definitions, the closest match is Call Transcript (CT) because it relates to the investors call, but since it is only an announcement of the audio recording, it is not a full transcript. However, there is no separate category for call recording announcements, so the best fit is Call Transcript (CT). Confidence is high due to clear references to the investors call and the nature of the document.
2023-09-25 English
Restructuring
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding a corporate restructuring transaction involving the acquisition of a business undertaking between two step-down wholly owned subsidiaries of the company. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, specifically Regulation 30, which pertains to disclosure of material events or information. The document includes details about the transaction, such as the memorandum of understanding, business transfer agreement, and financial consideration. It is an announcement of a material corporate event rather than a full financial report or detailed management discussion. The document length is 4233 characters, which is relatively short and consistent with a regulatory announcement. Therefore, this fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2023-09-25 English
Scheme of Arrangement
Capital/Financing Update Classification · 95% confidence The document is an official communication from Strides Pharma Science Limited to stock exchanges (BSE and NSE) dated September 25, 2023. It announces the approval by the Board of Directors of a Scheme of Arrangement involving a demerger of business divisions among related companies. The document references compliance with SEBI Listing Regulations and includes detailed disclosures about the scheme, shareholding patterns, rationale, and financial turnover of the divisions involved. It also includes an investor presentation titled 'Strides announces OneSource' that elaborates on the strategic rationale and expected benefits of the transaction. The content is focused on announcing a corporate restructuring transaction (Scheme of Arrangement) and providing detailed information about it to shareholders and regulators. This fits the category of Capital/Financing Update (CAP), as it relates to significant corporate restructuring and capital structure changes. The document is lengthy (15,000 characters) and contains substantive details, not merely an announcement of a report or a brief notice. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). It is not an M&A filing (MA or TAR) because it is a demerger scheme rather than a merger or acquisition per se, and the classification guidelines suggest such corporate restructuring announcements fall under CAP. Confidence in this classification is high due to the detailed nature of the disclosure and the regulatory context provided.
2023-09-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.